Cour Pharmaceuticals Development Co., Inc.

Check out our recent article published in BMJ Neurology Open authored by Samantha Brew, PhD, Molly Frey, MD, PhD, Derrick McCarthy, Adam Elhofy, and Richard Nowak, MD, MS It covers the rationale and design of our Phase 1b/2a #ClinicalTrial evaluating the potential of our antigen-specific immune tolerance treatment in development for #MyastheniaGravis (MG). Read here: https://bit.ly/3DMGvrk

We are delighted to kick-off 2025 having secured #OrphanDrugDesignation for our #nanoparticle CNP-104 for #PrimaryBiliaryCholangitis. With this designation, we aim to accelerate the advancement of a potential next generation disease-modifying therapy for people living with PBC: https://bit.ly/3C0qhdA

In case you missed it, our President and Chief Executive Officer, Dannielle Appelhans, recently spoke to Matthew Pillar of Bioprocess Online. Read the article linked in the post below to learn about our approach to treating #AutoimmuneDiseases with therapies developed using our #nanoparticle platform for antigen-specific immune tolerance.

Later this week, our Chief Medical Officer, Paul Peloso, M.D., will host an educational virtual event to discuss our nanoparticle technology and the ongoing #ClinicalTrial evaluating our potential treatment for #MyastheniaGravis. Register for the event here: https://bit.ly/4gkTtdH

Today we announced a strategic collaboration with Genentech to develop and commercialize an antigen-specific #nanoparticle therapy for the treatment of an undisclosed #AutoimmuneDisease. We look forward to working with another #biotech industry leader to advance a potentially disease-modifying medicine for the treatment of patients in need of a next generation therapy. Read more in our press release: https://bit.ly/4gzMheb

Our President and Chief Executive Officer, Dannielle Appelhans, and Chief Financial Officer, Brian Bock, will be at the 7th Annual Evercore HealthCONx Conference. They will be sharing the latest updates on the advancement of our antigen-specific immune tolerance treatments for #AutoimmuneDiseases. If you’re attending, be sure to catch COUR’s presentation or schedule a meeting via MeetMax.

Don’t forget - next Monday, November 18, our Chief Medical Officer, Paul Peloso, M.D., will present new #ClinicalData at American Association for the Study of Liver Diseases (AASLD)’s The Liver Meeting. Stop by our late-breaking poster to learn more on the topline results from the Phase 2a study of our candidate for #PrimaryBiliaryCholangitis: https://bit.ly/4heXsKb #TLM24

🌍 On #WorldDiabetesDay, we stand with those impacted by #Type1Diabetes. At COUR, we’re committed to advancing a potential new treatment to improve the lives of people living with #T1D. Learn more about #WDD2024 from the International Diabetes Federation: https://bit.ly/2oh9jlu #DiabetesLife

Don’t miss us at Immunology of Diabetes Society's #IDS2024 in Bruges, Belgium, from November 4-7! Our Chief Medical Officer, Paul Peloso, M.D., and Director of Immunology, Joe Podojil, Ph.D., are excited to connect with fellow industry leaders as they present updates on the advancement of our #Type1Diabetes program. Learn more about our nanoparticle in development as a potential treatment for #T1D: https://bit.ly/4f2r6RB

We have dosed the first patient in our Phase 1b/2a #ClinicalTrial evaluating our potential first-in-class, disease-modifying treatment that aims to induce antigen-specific tolerance in people living with #MyastheniaGravis. Learn more about the study here: https://bit.ly/4f21GDD